HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Carsten Denkert Selected Research

ErbB Receptors (EGF Receptor)

4/2024Quality-Assured Analysis of PIK3CA Mutations in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Tissue: A Story About the Need for Proficiency Testing for High-Quality Molecular Biomarker Reporting in Precision Medicine.
1/2023Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.
1/2023Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 Therapy.
10/2021Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2).
10/2021Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial.
1/2016Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy.
3/2015Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.
8/2013From High-Throughput Microarray-Based Screening to Clinical Application: The Development of a Second Generation Multigene Test for Breast Cancer Prognosis.
8/2013Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.
1/2010KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Carsten Denkert Research Topics

Disease

194Neoplasms (Cancer)
04/2024 - 03/2002
164Breast Neoplasms (Breast Cancer)
04/2024 - 06/2003
55Carcinoma (Carcinomatosis)
02/2024 - 03/2002
37Ovarian Neoplasms (Ovarian Cancer)
04/2024 - 10/2002
36Triple Negative Breast Neoplasms
04/2024 - 01/2013
19Pathologic Complete Response
11/2023 - 05/2012
13Neoplasm Metastasis (Metastasis)
11/2023 - 11/2007
12Adenocarcinoma
11/2023 - 01/2003
8Colorectal Neoplasms (Colorectal Cancer)
01/2019 - 01/2003
7Carcinogenesis
01/2021 - 06/2005
6Ovarian Epithelial Carcinoma
01/2023 - 11/2007
5Colonic Neoplasms (Colon Cancer)
01/2023 - 09/2005
4Residual Neoplasm
09/2022 - 06/2009
4Pancreatic Neoplasms (Pancreatic Cancer)
08/2016 - 01/2005
3Lymphatic Metastasis
02/2024 - 04/2006
3Neuroendocrine Carcinoma
02/2024 - 10/2021
3Inflammation (Inflammations)
10/2022 - 02/2004
3Renal Cell Carcinoma (Grawitz Tumor)
10/2022 - 09/2005
3Disease Progression
01/2020 - 04/2005
3Noninfiltrating Intraductal Carcinoma (DCIS)
10/2019 - 04/2012
3Melanoma (Melanoma, Malignant)
11/2017 - 01/2002
3Stomach Neoplasms (Stomach Cancer)
05/2012 - 04/2006
3Prostatic Neoplasms (Prostate Cancer)
02/2008 - 08/2004
3Adenoma (Adenomas)
02/2005 - 06/2002

Drug/Important Bio-Agent (IBA)

54Biomarkers (Surrogate Marker)IBA
04/2024 - 06/2005
52Proteins (Proteins, Gene)FDA Link
11/2023 - 03/2002
38Estrogen ReceptorsIBA
04/2024 - 06/2003
35Hormones (Hormone)IBA
04/2024 - 01/2009
34Messenger RNA (mRNA)IBA
10/2022 - 03/2002
22ParaffinIBA
07/2020 - 06/2002
21taxaneIBA
10/2021 - 01/2007
19human ERBB2 proteinIBA
01/2023 - 01/2009
18Paclitaxel (Taxol)FDA LinkGeneric
01/2023 - 04/2006
18Formaldehyde (Formol)FDA Link
07/2020 - 09/2003
17Cyclophosphamide (Cytoxan)FDA LinkGeneric
01/2023 - 04/2006
15AnthracyclinesIBA
07/2020 - 01/2009
14Phenobarbital (Luminal)FDA Link
12/2023 - 11/2010
14Immune Checkpoint InhibitorsIBA
01/2023 - 03/2016
13Carboplatin (JM8)FDA LinkGeneric
01/2023 - 06/2014
13Trastuzumab (Herceptin)FDA Link
01/2023 - 07/2011
13Epirubicin (Ellence)FDA LinkGeneric
01/2023 - 01/2012
13RNA (Ribonucleic Acid)IBA
01/2023 - 10/2002
11130-nm albumin-bound paclitaxelIBA
11/2023 - 10/2015
11Cyclooxygenase 2 (Cyclooxygenase-2)IBA
01/2009 - 03/2002
10ErbB Receptors (EGF Receptor)IBA
04/2024 - 01/2010
10Progesterone Receptors (Progesterone Receptor)IBA
02/2023 - 01/2009
10Protein Isoforms (Isoforms)IBA
04/2022 - 06/2003
10PlatinumIBA
11/2021 - 01/2007
9DNA (Deoxyribonucleic Acid)IBA
01/2021 - 11/2009
8LipidsIBA
05/2021 - 09/2008
7Poly(ADP-ribose) Polymerase InhibitorsIBA
01/2023 - 06/2011
7Doxorubicin (Adriamycin)FDA LinkGeneric
10/2022 - 04/2006
6Bevacizumab (Avastin)FDA Link
01/2023 - 01/2012
5Phosphotransferases (Kinase)IBA
04/2024 - 01/2002
5Epidermal Growth Factor (EGF)IBA
12/2023 - 02/2017
5LigandsIBA
11/2023 - 09/2014
5GemcitabineFDA Link
01/2021 - 08/2016
5Carrier Proteins (Binding Protein)IBA
10/2020 - 05/2009
5Histone Deacetylases (Histone Deacetylase)IBA
04/2013 - 02/2008
5Histone Deacetylase InhibitorsIBA
11/2009 - 02/2008
5Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA
03/2007 - 06/2003
4Poly Adenosine Diphosphate RiboseIBA
04/2024 - 06/2011
4ElementsIBA
02/2024 - 11/2015
4Eosine Yellowish-(YS) (Eosin)IBA
02/2024 - 09/2017
4Immunoconjugates (Immunoconjugate)IBA
11/2023 - 01/2021
4EnzymesIBA
10/2023 - 03/2002
4Cisplatin (Platino)FDA LinkGeneric
11/2022 - 04/2006
4B7-H1 AntigenIBA
12/2021 - 01/2016
4MicroRNAs (MicroRNA)IBA
10/2018 - 02/2010
4Glutamine (L-Glutamine)FDA Link
01/2016 - 11/2012
4ELAV-Like Protein 1IBA
02/2008 - 01/2004
4Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA
04/2006 - 03/2002
4Polo-Like Kinase 1IBA
04/2006 - 08/2004
3durvalumabIBA
04/2024 - 01/2021
3Hematoxylin (Haematoxylon)IBA
02/2024 - 09/2017
3Transcription Factors (Transcription Factor)IBA
02/2024 - 10/2020
3DenosumabFDA Link
11/2023 - 01/2022
3SynaptophysinIBA
11/2023 - 10/2021
3pembrolizumabIBA
11/2023 - 01/2020
3Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
04/2022 - 01/2012
3liposomal doxorubicin (Doxil)FDA Link
01/2022 - 01/2019
3CytokinesIBA
01/2022 - 01/2002
3Matrix Metalloproteinases (MMPs)IBA
01/2022 - 05/2003
3Estrogens (Estrogen)FDA Link
01/2021 - 12/2009
3Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA
07/2020 - 10/2014
3Androgen Receptors (Androgen Receptor)IBA
02/2020 - 11/2011
3Indicators and Reagents (Reagents)IBA
04/2017 - 02/2008
3InterferonsIBA
01/2017 - 01/2013
3Glutamic Acid (Glutamate)FDA Link
01/2016 - 12/2013
3Fluorouracil (Carac)FDA LinkGeneric
10/2015 - 04/2006
3Docetaxel (Taxotere)FDA Link
08/2013 - 11/2011
3leptomycin BIBA
07/2011 - 02/2008
3ProstaglandinsIBA
02/2004 - 03/2002

Therapy/Procedure

97Therapeutics
04/2024 - 05/2003
75Neoadjuvant Therapy
02/2024 - 01/2009
56Drug Therapy (Chemotherapy)
12/2023 - 01/2005
12Immunotherapy
04/2022 - 01/2013
7Adjuvant Chemotherapy
01/2021 - 12/2009
5Aftercare (After-Treatment)
11/2018 - 02/2005
3Radiotherapy
02/2024 - 11/2019